Lutetium 177‑DOTA‑TATE therapy for esthesioneuroblastoma: A case report

  • Authors:
    • Juliano Guerra Sabongi
    • Mônica Carboni Pereira Gonçalves
    • Cira Danielle Casado Alves
    • João Alves
    • Cristovam Scapulatempo‑Neto
    • Sonia Marta Moriguchi
  • View Affiliations

  • Published online on: September 20, 2016     https://doi.org/10.3892/etm.2016.3732
  • Pages: 3078-3082
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare malignant tumor that accounts for 3% of all tumors of the nasal cavity. The incidence of ENB is 0.4 cases per million in the general population, and the most common symptoms are nasal obstruction and epistaxis. Previous studies have indicated the presence of somatostatin receptors in this tumor type. Common treatment strategies for ENB include resection and adjuvant radiotherapy and/or chemotherapy (combined treatment); however, the rate of recurrence is high. Treatment of neuroendocrine tumors using radionuclides bound to somatostatin analogues is well established in clinical practice. However, a standard and effective therapeutic approach has not been reported for ENB. The current study described the case of a 74‑year‑old female with numerous recurrences of ENB following multiple treatments and without possibility of resection. The patient was treated with the radiolabeled‑somatostatin analogue, 177Lutetium‑DOTA‑octreotate (177Lu‑DOTA‑TATE), which successfully controlled the disease. This suggests that 177Lu‑DOTA‑TATE is a potential treatment for ENB and may represent an effective alternative and novel therapeutic strategy for this disease.
View Figures
View References

Related Articles

Journal Cover

November-2016
Volume 12 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sabongi JG, Gonçalves MC, Alves CD, Alves J, Scapulatempo‑Neto C and Moriguchi SM: Lutetium 177‑DOTA‑TATE therapy for esthesioneuroblastoma: A case report. Exp Ther Med 12: 3078-3082, 2016.
APA
Sabongi, J.G., Gonçalves, M.C., Alves, C.D., Alves, J., Scapulatempo‑Neto, C., & Moriguchi, S.M. (2016). Lutetium 177‑DOTA‑TATE therapy for esthesioneuroblastoma: A case report. Experimental and Therapeutic Medicine, 12, 3078-3082. https://doi.org/10.3892/etm.2016.3732
MLA
Sabongi, J. G., Gonçalves, M. C., Alves, C. D., Alves, J., Scapulatempo‑Neto, C., Moriguchi, S. M."Lutetium 177‑DOTA‑TATE therapy for esthesioneuroblastoma: A case report". Experimental and Therapeutic Medicine 12.5 (2016): 3078-3082.
Chicago
Sabongi, J. G., Gonçalves, M. C., Alves, C. D., Alves, J., Scapulatempo‑Neto, C., Moriguchi, S. M."Lutetium 177‑DOTA‑TATE therapy for esthesioneuroblastoma: A case report". Experimental and Therapeutic Medicine 12, no. 5 (2016): 3078-3082. https://doi.org/10.3892/etm.2016.3732